Table 2 Patient characteristics, vasoactive use and fluid balance in ICU patients with oliguric AKI

Age (years; median (IQR))

69 (61–78)

70 (59–77)

0.647

Male (%)

41 (75.9)

335 (69.2)

0.351

Body weight (kg; median (IQR))

62.0 (52.3–67.8)

60.0 (50.0–70.0)

0.571

 Immunocompromised

8 (14.8)

42 (8.7)

0.141

 Hematologic malignancy

2 (3.7)

12 (2.5)

0.642

 Metastasis

0 (0.0)

14 (2.9)

0.380

 Respiratory failure

3 (5.6)

19 (3.9)

0.476

 Heart failure

0 (0.0)

2 (0.4)

1.000

 Liver failure

3 (5.6)

8 (1.7)

0.088

 Operating room

18 (33.3)

260 (53.7)

0.008

  Cardiac surgery

10 (18.5)

127 (26.2)

  Thoracic surgery

2 (3.7)

42 (8.7)

  Neurosurgery

0 (0.0)

31 (6.4)

  Other major surgery

6 (11.1)

60 (12.4)

 General ward

21 (38.9)

109 (22.5)

 Emergency department

15 (27.8)

115 (23.8)

Sepsis at ICU admission (%)

27 (50.0)

111 (22.9)

<0.001

Serum creatinine at ICU admission (mg/dL; median (IQR))

1.54 (1.04–3.10)

0.86 (0.67–1.19)

<0.001

Time to oliguric AKI (hours; median (IQR))

10.7 (7.4–28.5)

19.0 (10.7–35.5)

0.001

APACHE II score (median (IQR))

22 (17–27)

17 (13–21)

<0.001

SOFA score (median (IQR))

11 (8–13)

7 (4–9)

<0.001

 Respiratory

2 (1–3)

2 (1, 2)

0.182

 Coagulation

2 (0–2)

1 (0–2)

0.009

 Liver

1 (0–1)

0 (0–1)

0.098

 Cardiovascular

4 (1–4)

3 (1–4)

0.040

 Central nervous system

0 (0–1)

0 (0–1)

0.130

 Renal

3 (1–3)

0 (0–1)

<0.001

 Dopamine (%)

0 (0.0)

10 (2.1)

0.609

 Dobutamine (%)

9 (16.7)

97 (20.0)

0.718

 Norepinephrine (%)

36 (66.7)

205 (42.4)

0.001

 Vasopressin (%)

6 (11.1)

14 (2.9)

0.010

 In (mL; median (IQR))

949 (691–1526)

758 (530–1096)

0.004

 Out (mL; median (IQR))

272 (158–413)

326 (200–506)

0.028

 Balance (mL; median (IQR))

723 (386–1278)

432 (179–759)

<0.001